Urologic Oncology: Seminars and Original Investigations This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Improving the genetic signature of prostate cancer, the somatic mutations
Somatic mutations have been related to the highest incidence of metastatic disease and different treatment responses. The molecular cause of prostate cancer (PC) is still unclear; however, its progression involves alterations in oncogenes and tumor suppressor genes as well as somatic mutations such as the ones in PIK3CA gene. A high percentage of PC is considered sporadic, which means that the damage to the genes occurs by chance after birth (mainly somatic mutations will drive the cancer event). (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - April 9, 2018 Category: Urology & Nephrology Authors: Luis Javier Martinez-Gonzalez, Manrique Pascual Geler, Inmaculada Robles Fernandez, Jose Manuel Cozar, Jose Antonio Lorente, Maria Jesus Alvarez Cubero Tags: Original article Source Type: research

Molecular basis of the effect of MMP-9 on the prostate bone metastasis: A review
Prostate cancer (PCa) is the second most common cancer in men especially after 50 years old. The metastasis of said cancer involves a rise for morbidity, metastasizing 90% of the occasions on bone. Metalloproteinases (MMPs) are involved in the process of bone formation and they are postulated to be involved in the process of metastasizing, in particular MMP-9. This work is justified taking into account the scientific interest of the subject and the quality of the literature sources used. PCa generates a high morbidity and mortality in men, especially due to the process of metastasis, resulting in effects to health and soci...
Source: Urologic Oncology: Seminars and Original Investigations - April 9, 2018 Category: Urology & Nephrology Authors: Emilio Rub én Pego, Isaac Fernández, María Jesús Núñez Tags: Review article Source Type: research

Improved surgical outcomes following radical cystectomy at high-volume centers influence overall survival
Positive surgical margins (PSM) and lymph node yield (LNY) following radical cystectomy (RC) for urothelial carcinoma of the bladder affect survival. Variations in PSM or LNY at different care facilities are poorly described. We evaluated the relationship between hospital surgical volume and academic hospital status with these surgical outcomes and overall survival (OS). (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - April 5, 2018 Category: Urology & Nephrology Authors: Kyle Scarberry, Nicholas G. Berger, Kelly B. Scarberry, Shree Agrawal, John J. Francis, Jessica M. Yih, Christopher M. Gonzalez, Robert Abouassaly Tags: Original article Source Type: research

Sociodemographic disparities in chemotherapy treatment and impact on survival among patients with metastatic bladder cancer
To evaluate how socioeconomic status and other demographic factors are associated with the receipt of chemotherapy and subsequent survival in patients diagnosed with metastatic bladder cancer. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - April 5, 2018 Category: Urology & Nephrology Authors: Amy Klapheke, Stanley A. Yap, Kevin Pan, Rosemary D. Cress Tags: Original article Source Type: research

Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer
Docetaxel chemotherapy is a standard treatment for castration-resistant prostate cancer (CRPC). Rapidly expanding treatment options for CRPC provide reasonable alternatives for those who are resistant to docetaxel. Therefore, prediction of docetaxel resistance has become of great clinical importance. Syndecan-1 (SDC1) has been currently shown to be involved in chemotherapy resistance in various malignancies including prostate cancer. The predicting value of serum SDC1 level has not been evaluated yet. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - April 5, 2018 Category: Urology & Nephrology Authors: Tibor Szarvas, Sabina Sevcenco, Orsolya M ódos, Dávid Keresztes, Péter Nyirády, András Kubik, Miklós Romics, Ilona Kovalszky, Henning Reis, Boris Hadaschik, Shahrokh F. Shariat, Gero Kramer Tags: Original article Source Type: research

Syndecan-1 shedding circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer
Docetaxel chemotherapy is a standard treatment for castration-resistant prostate cancer (CRPC). Rapidly expanding treatment options for CRPC provide reasonable alternatives for those who are resistant to docetaxel. Therefore, prediction of docetaxel resistance has become of great clinical importance. Syndecan-1 (SDC1) has been currently shown to be involved in chemotherapy resistance in various malignancies including prostate cancer. The predicting value of serum SDC1 level has not been evaluated yet. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - April 5, 2018 Category: Urology & Nephrology Authors: Tibor Szarvas, Sabina Sevcenco, Orsolya M ódos, Dávid Keresztes, Péter Nyirády, András Kubik, Miklós Romics, Ilona Kovalszky, Henning Reis, Boris Hadaschik, Shahrokh F. Shariat, Gero Kramer Tags: Original article Source Type: research

Lymph node yield during radical prostatectomy does not impact rate of biochemical recurrence in patients with seminal vesicle invasion and node-negative disease
Seminal vesicle invasion (SVI) is a risk factor for poor oncologic outcome in patients with prostate cancer. Modifications to the pelvic lymph node dissection (PLND) during radical prostatectomy (RP) have been reported to have a therapeutic benefit. The present study is the first to determine if lymph node yield (LNY) is associated with a lower risk of biochemical recurrence (BCR) for men with SVI. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - April 3, 2018 Category: Urology & Nephrology Authors: Ketan K. Badani, Balaji N. Reddy, Eric J. Moskowitz, David J. Paulucci, Alp Tuna Beksac, Alberto Martini, Michael J. Whalen, Douglas W. Skarecky, Linda My Huynh, Thomas E. Ahlering Tags: Original article Source Type: research

Cover 2 - Masthead
(Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - April 1, 2018 Category: Urology & Nephrology Source Type: research

Editorial Board
(Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - April 1, 2018 Category: Urology & Nephrology Source Type: research

Table of Contents
(Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - April 1, 2018 Category: Urology & Nephrology Source Type: research